Molnlycke Health Care

NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections Steriwave puts control of a critical part of infection prevention in the hands of clinical teams at the point of care.” — Carolyn Cross, CEO Ondine Biomedical GLASGOW, UNITED KINGDOM, August 3, 2026 / EINPresswire.com / -- Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an innovative light-activated therapy to protect patients from surgical site infections (SSIs). The hospital, which carries out approximately 30% of all hip and knee replacements in Scotland, is integrating Steriwave ® nasal photodisinfection into its care pathway prior to surgery. Developed by Vancouver-based Ondine Biomedical and distributed in the UK by Mölnlycke Health Care, the technology replaces traditional multi-day, home-based nasal decolonisation kits with a single five-minute treatment administered by a nurse immediately before surgery. The nose is a primary reservoir for harmful pathogens that cause post-operative joint infections. Steriwave utilises a patented, light-sensitive liquid compound in combination with a specific wavelength of red light to generate oxygen-free radicals that rapidly eliminate bacteria, viruses, and fungi without relying on antibiotics—a critical factor in the global fight against drug-resistant "superbugs." The action is so rapid and multifaceted that the bugs are unable to develop resistance. Uncomplicated joint replacements at NHS Golden Jubilee typically involve an average hospital stay of 2.4 days. However, UK research indicates that when a prosthetic joint infection occurs, the resulting revision surgery and ongoing treatment can cost the NHS over £33,000 per patient over five years. "Preventing surgical site infections is a critical component of our approach," said Professor Christopher Gee, Consultant Orthopaedic Surgeon at NHS Golden Jubilee. "By integrating nasal photodisinfection into our infection-prevention bundle, we offer an efficient, nurse-led solution that enhances patient outcomes and optimises healthcare resources." The move directly aligns with the Scottish Government's health objectives to increase elective surgical capacity, optimise National Treatment Centres, and reduce waiting lists across the country. "In high-volume elective surgery, every infection prevented protects both patients and capacity," said Carolyn Cross, CEO of Ondine Biomedical. "Steriwave puts control of a critical part of infection prevention in the hands of clinical teams at the point of care." Steriwave is now deployed in hospitals across Canada and in England, both to prevent surgical site infections and to protect patients in ICUs who are particularly vulnerable to infection. ENDS NOTES TO EDITORS For media information contact: Simon Vane Percy simon@vanepercy.com + 44 (0) 7710 005 910 About Ondine Biomedical Inc: Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (‘photodisinfection’) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development. Ondine’s nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave ® . In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. About Steriwave ® Steriwave uses a patented photodisinfection process. A light-activated photosensitizer is applied to the nasal passages and activated by a specific wavelength of red light, triggering an oxidative burst that eliminates bacteria, viruses, and fungi in minutes. While investigational in the U.S., the technology is already successfully deployed in leading hospitals across the UK, EU, and Canada. *The tradename Steriwave is used worldwide but will be subject to US-specific branding following FDA approval. S J VANE PERCY VANE PERCY & ROBERTS email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

PEACHTREE CORNERS, Ga., July 7, 2026 /PRNewswire/ -- Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company's U.S. presence, the portfolio expansion also supports long-term value creation across key market segments. Driven by the ambition to deliver customer-centric innovation, the launches reinforce Mölnlycke's commitment to advancing standards in wound care and patient handling in the U.S. Mölnlycke product launches since the start of 2026: Granudacyn ® Wound Wash Solution Tortoise ® Lite Turning and Positioning System Mepi ® Press 2 & Mepi ® Press Lite Compression System In a healthcare environment facing increasing operational pressure and workforce constraints, Mölnlycke focuses on solutions that strengthen value-based care delivery across acute and out-of-hospital care settings. These innovations address key challenges for healthcare professionals, including better clinical and operational outcomes, safe patient handling and consistent wound management. Each of the new offerings plays a strategic role: Granudacyn ® Wound Wash Solution: A biocompatible, non-cytotoxic wound cleanser offers a gentle and effective way to cleanse both acute and chronic wounds, reducing discomfort and simplifying wound care. For clinicians and caregivers, this means safe wound preparation that fits seamlessly into existing protocols. Tortoise ® Lite Turning and Positioning System: A simplified, ergonomic system that supports safe and effective patient repositioning. Designed to remain under the patient throughout care, Tortoise® Lite aims to reduce caregiver strain and promote consistent pressure relieving practices. Mepi ® Press 2 & Mepi ® Press 2 Lite Compression System: A multi-layer solution designed to deliver consistent compression therapy across a wide range of patient needs for venous disease and edema. Together with Mölnlycke advanced Mepilex® Up wound dressings and Granudacyn Wound Wash, Mepi Press 2 seamlessly integrates into care protocols, strengthening the end-to-end venous leg ulcer management for clinicians and improving clinical outcomes for patients. "2026 marks an important year in our strategy to expand access to safe, intuitive and clinically reliable solutions," said Craig Kennedy, Vice President Commercial Wound Care - Americas at Mölnlycke Health Care. "With these three major launches, we are reinforcing our mission to elevate standard of care and equip healthcare professionals with tools that make a meaningful impact in both patient outcomes and care delivery." Each product will be available through Mölnlycke Health Care U.S. and authorized distribution partners, Note to editors Media background documents for each product are available upon request or can be accessed via the Mölnlycke Health Care US media room. For more information, please contact: Jamie Smith Media Relations Manager Email [email protected] About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. This information was brought to you by Cision The following files are available for download: SOURCE Mölnlycke 21% more press release views with Request a Demo

Clinical learning Embracing partnerships Innovation Our expertise Our governance Our purpose Clinical learning Embracing partnerships Innovation Our expertise Our governance Our purpose Application process Departments and open roles Diversity, Equity and Inclusion How we help you thrive Life at Mölnlycke Application process Departments and open roles Diversity, Equity and Inclusion How we help you thrive Life at Mölnlycke Code of conduct and policies Commitments and recognition Ethics Hotline Governance Revolutionising care for planet Sustainability reporting and governance Sustainable healthcare solutions Sustainable supply chains Code of conduct and policies Commitments and recognition Ethics Hotline Governance Revolutionising care for planet Sustainability reporting and governance Sustainable healthcare solutions Sustainable supply chains Global events Media room Mölnlycke news Global events Media room Mölnlycke news The changes reflect Mölnlycke’s continued focus on ensuring strong governance and relevant expertise as the company advances its growth journey and works to fulfil its purpose to revolutionise care for people and planet. “We would like to thank Christian for his valuable contribution to the Mölnlycke Board and welcome Filippa and Thomas in their new roles,” said Karl-Henrik Sundström, Chairman of the Board. “Their experience and perspectives will support Mölnlycke as we continue to develop as a world-leading MedTech company.” Filippa Stenberg currently serves as Managing Director of Patricia Industries, part of Investor AB, and brings extensive experience in active ownership and healthcare investments. She has served as deputy board member of Mölnlycke since 22 May 2025. Born in 1985, Filippa is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. Her board assignments include Swedish Orphan Biovitrum AB, Affibody Medical AB and Atlas Antibodies AB. Thomas Kidane will join the Mölnlycke Board as deputy board member. Born in 1986, he is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. He is Co-Head of Patricia Industries, a member of Investor AB’s Executive Leadership Team, and serves on the boards of Permobil, Piab Group and Fortnox. For more information, please contact: Media Relations Email: jamie.smith@molnlycke.com Phone: +46 723 757507 Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability. Gothenburg, Sweden, and Shanghai, China. 21 May 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England. Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect. Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet. Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU. Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO. A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045. Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in Medtech, headquarted in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company's production sites in the Czech Republic. Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. © 2026 Mölnlycke AB Get knowledge, learn about our products, get support and more. Australia Austria Belgium (Dutch) Belgium (French) Brasil Canada (English) Canada (French) Chile China Czechia Denmark Estonia Finland France Germany Hungary India Italy Japan Latvia Lithuania Malaysia Netherlands (Dutch) New Zealand Norway Poland Portugal Singapore South Korea Spain Sweden Switzerland (French) Switzerland (german) United Arab Emirates United Kingdom United States No markets Find jobs, our financial reports and more.